• Skip to main content
Indalo Therapeutics
  • About Us
    • Overview
    • Management
    • Board of Directors
    • Investors
    • Advisors
    • Academic Founders
  • Pipeline
    • Our Programs
    • Fibrotic Disease
  • Our Science
    • Targeting Integrins for Fibrosis
    • Publications
  • News
    • Articles
    • Press Releases
  • Contact Us
Our Programs
  • Pipeline
  • Our Programs
  • Fibrotic Disease

Our Programs: Pipeline

Indalo’s lead drug candidate, IDL-2965, is an oral, selective antagonist of RGD-binding integrins avb1, avb3, and avb6 that uniquely inhibits multiple processes of pathologic fibrosis, including the local activation of TGF-b by both epithelial cells and fibroblasts, as well as the ability of stiff extracellular matrix to promote fibroblast migration and survival.

IDL-2965 recently demonstrated excellent safety, tolerability, and oral pharmacokinetics in healthy volunteers. Dosing has initiated in a proof-of-biology study in IPF patients in preparation for the initiation of late-stage pivotal trials. Studies in NASH patient are planned for 2020.

In preclinical models, IDL-2965 provides potent antifibrotic efficacy at low once-daily oral doses across multiple animal models of disease in vital organ systems, including lung, liver, and kidney.

Our Programs: Mouse liver fibrosis from CCl4 with IDL-2965
Our Programs: Mouse liver fibrosis from CCl4 without IDL-2965

Rat liver fibrosis from CCl4 with and without treatment with IDL-2965.

Indalo Therapeutics

Privacy Policy • Terms of Use • Sitemap
© 2019 Indalo Therapeutics, Inc.
Website Design & Development, Graphic Beans